Product image of Linoladiol-H N (Estradiol Hemihydrate, Prednisolone Sesquihydrate) supplied by GNH India

Linoladiol-H N

Active Ingredient:
Estradiol Hemihydrate, Prednisolone Sesquihydrate
Origin:
EU

Linoladiol-H N (Estradiol Hemihydrate, Prednisolone Sesquihydrate)

Estradiol hemihydrate and prednisolone sesquihydrate, the active ingredients in Linoladiol-H N, are an estrogen and a corticosteroid presented as a topical formulation for skin application. It treats estrogen deficiency and inflammatory skin conditions in adult women.

GNH India supplies Linoladiol-H N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Dr. August Wolff Gmbh & Co. Kg Arzneimittel

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Linoladiol-H N combines an estrogen and a corticosteroid and is used in therapeutic areas that involve hormonal regulation and inflammation.
  • Menopausal estrogen deficiency: provides localized estrogen to relieve urogenital atrophy and dryness.
  • Inflammatory dermatoses: reduces redness, swelling and itching associated with eczema or contact dermatitis.
  • Post‑menopausal skin aging: improves skin elasticity and hydration through estrogenic effects.

How It Works

  • Estradiol hemihydrate binds to estrogen receptors (ERα and ERβ) acting as an agonist, thereby promoting gene transcription that supports tissue integrity and moisture. Prednisolone sesquihydrate engages glucocorticoid receptors, inhibiting phospholipase A2 and downstream prostaglandin and cytokine production, resulting in anti‑inflammatory and immunosuppressive effects at the site of application.

Side Effects

Common Side Effects

  • Local skin irritation or burning sensation.
  • Mild itching or pruritus.
  • Dryness or peeling of the applied area.
  • Transient erythema.
  • Hyperpigmentation at the site.
  • Folliculitis or mild acneiform eruption.

Serious or Rare Side Effects

  • Allergic contact dermatitis with swelling and vesiculation.
  • Severe skin atrophy or thinning.
  • Systemic estrogenic effects such as thromboembolic events.
  • Adrenal suppression with prolonged use.
  • Cushingoid appearance or systemic corticosteroid toxicity.
  • Secondary bacterial or fungal infection of the treated skin.

Precautions & Warnings

Before using Linoladiol-H N, consider the following precautions:

  • Pregnancy: avoid use unless the prescriber determines benefits outweigh potential risks.
  • Breastfeeding: not recommended due to possible transfer of active ingredients.
  • Known hypersensitivity: discontinue immediately if allergic reaction occurs.
  • Infected or broken skin: do not apply on areas with active infection or open wounds.
  • Hormone‑sensitive conditions: use with caution in patients with a history of estrogen‑dependent tumors.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Linoladiol-H N may interact with other medicines as follows:

Major Interactions (Avoid)

  • Oral systemic estrogen therapy: increased risk of thromboembolic events.
  • Systemic corticosteroids: additive immunosuppression and adrenal suppression.
  • Antifungal azoles (e.g., ketoconazole): may raise local corticosteroid concentrations.

Moderate Interactions (Monitor Closely)

  • CYP450 enzyme inducers (e.g., rifampicin): may reduce corticosteroid efficacy.
  • Hormonal contraceptives: possible reduction in contraceptive effectiveness.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs) applied nearby: may increase local skin irritation.

Frequently Asked Questions

Linoladiol-H N is a topical combination of estradiol hemihydrate and prednisolone sesquihydrate designed to address estrogen deficiency‑related skin changes and to provide local anti‑inflammatory relief for conditions such as eczema, dermatitis, and post‑menopausal skin aging.

Estradiol hemihydrate acts as an estrogen receptor agonist. By binding to ERα and ERβ in skin cells, it stimulates gene expression that promotes tissue hydration, collagen synthesis, and maintenance of the epithelial barrier, helping to reverse estrogen‑related skin atrophy.

The appropriate dose of Linoladiol-H N is determined by the prescribing healthcare professional based on the patient’s condition, age, and response. The prescriber will specify the amount to apply, frequency, and duration of therapy.

Safety in pregnancy and lactation has not been established. The product should be avoided unless the prescriber judges that the potential benefit justifies any possible risk to the fetus or infant.

To place an order, submit an enquiry on the Linoladiol-H N product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Unlike single‑ingredient estrogen creams, Linoladiol-H N combines estrogen with a corticosteroid, offering both hormonal restoration and anti‑inflammatory action in one formulation. This dual mechanism can be advantageous for patients who need estrogenic skin benefits while also requiring control of inflammation.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Keep it away from direct sunlight, moisture, and heat sources to maintain stability and potency.

Linoladiol-H N is applied topically to the affected skin area. The prescriber will advise the amount to use per application, the frequency (e.g., once or twice daily), and the total duration of treatment.

Serious risks include severe allergic reactions, systemic estrogenic effects such as thromboembolic events, adrenal suppression from the corticosteroid component, and secondary skin infections. Patients should report any signs of swelling, severe rash, unexplained bruising, or infection promptly.

Linoladiol-H N should not be used by individuals with known hypersensitivity to estradiol, prednisolone, or any excipients, by patients with active skin infections at the application site, and by those with a history of estrogen‑dependent tumors unless specifically directed by a specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Estradiol Hemihydrate, Prednisolone Sesquihydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT